DaVita Inc. (NYSE:DVA) Shares Sold by Dumont & Blake Investment Advisors LLC

Dumont & Blake Investment Advisors LLC lessened its position in shares of DaVita Inc. (NYSE:DVA) by 50.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,056 shares of the company’s stock after selling 7,094 shares during the quarter. Dumont & Blake Investment Advisors LLC’s holdings in DaVita were worth $1,157,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Blue Trust Inc. lifted its position in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. purchased a new stake in shares of DaVita in the second quarter worth about $43,000. Versant Capital Management Inc lifted its holdings in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Friedenthal Financial acquired a new position in shares of DaVita in the 2nd quarter valued at $48,000. Finally, Point72 Hong Kong Ltd purchased a new position in DaVita in the second quarter valued at $68,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 over the last ninety days. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DVA. Bank of America upped their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Finally, UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, DaVita presently has an average rating of “Hold” and a consensus target price of $159.00.

DaVita Trading Down 2.3 %

Shares of DVA traded down $3.78 during midday trading on Friday, reaching $157.60. The company had a trading volume of 9,580 shares, compared to its average volume of 798,917. The firm has a 50 day simple moving average of $157.95 and a 200-day simple moving average of $145.34. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The stock has a market cap of $13.22 billion, a PE ratio of 17.19, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. DaVita Inc. has a 1-year low of $75.47 and a 1-year high of $168.50.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.08 EPS. Research analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.